Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04326439 |
| Title | AflacLL1901 (CHOA-AML) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Emory University |
| Indications | |
| Therapies |
Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin |
| Age Groups: | child | adult |
| Covered Countries | USA |
CKB BOOST